Table of Contents Author Guidelines Submit a Manuscript
Advances in Chemistry
Volume 2015, Article ID 859730, 21 pages
http://dx.doi.org/10.1155/2015/859730
Review Article

Anticancer Activities of Mononuclear Ruthenium(II) Coordination Complexes

1Department of Chemistry, Faculty of Science and Agriculture, University of Fort Hare, Private Bag X1314, Alice 5700, South Africa
2Botswana Institute for Technology Research and Innovation, Private Bag 0082, Gaborone, Botswana

Received 10 October 2014; Revised 18 December 2014; Accepted 25 January 2015

Academic Editor: M. Paula Robalo

Copyright © 2015 William M. Motswainyana and Peter A. Ajibade. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Rosenberg, L. van Camp, and T. Krigas, “Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode,” Nature, vol. 205, no. 4972, pp. 698–699, 1965. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Rosenberg, L. VanCamp, J. E. Trosko, and V. H. Mansour, “Platinum compounds: a new class of potent antitumour agents,” Nature, vol. 222, pp. 385–386, 1969. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Alama, B. Tasso, F. Novelli, and F. Sparatore, “Organometallic compounds in oncology: implications of novel organotins as antitumor agents,” Drug Discovery Today, vol. 14, no. 9-10, pp. 500–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. T. V. Segapelo, I. A. Guzei, L. C. Spencer, W. E. V. Zyl, and J. Darkwa, “(Pyrazolylmethyl)pyridine platinum(II) and gold(III) complexes: synthesis, structures and evaluation as anticancer agents,” Inorganica Chimica Acta, vol. 362, no. 9, pp. 3314–3324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. W. Hambley, “The influence of structure on the activity and toxicity of Pt anti-cancer drugs,” Coordination Chemistry Reviews, vol. 166, pp. 181–223, 1997. View at Publisher · View at Google Scholar
  6. S. H. van Rijt and P. J. Sadler, “Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs,” Drug Discovery Today, vol. 14, no. 23-24, pp. 1089–1097, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Jakupec, M. Galanski, V. B. Arion, C. G. Hartinger, and B. K. Keppler, “Antitumour metal compounds: more than theme and variations,” Dalton Transactions, no. 2, pp. 183–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Kostova, “Ruthenium complexes as anticancer agents,” Current Medicinal Chemistry, vol. 13, no. 9, pp. 1085–1107, 2006. View at Publisher · View at Google Scholar
  9. I. Ott and R. Gust, “Non platinum metal complexes as anti-cancer drugs,” Archiv der Pharmazie, vol. 340, no. 3, pp. 117–126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Griffith, S. Cecco, E. Zangrando, A. Bergamo, G. Sava, and C. J. Marmion, “Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation,” Journal of Biological Inorganic Chemistry, vol. 13, no. 4, pp. 511–520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Margalit, H. B. Gray, M. J. Clarke, and L. Podbielski, “Chemical and biological properties of pentaammineruthenium-bleomycin complexes,” Chemico-Biological Interactions, vol. 59, no. 3, pp. 231–245, 1986. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Zhang, J. Chen, and Y. Liang, “DNA binding, cytotoxicity, and apoptotic-inducing activity of ruthenium(II) polypyridyl complex,” Acta Biochimica et Biophysica Sinica, vol. 42, no. 7, pp. 440–449, 2010. View at Publisher · View at Google Scholar
  13. J. Reedijk, “Metal-ligand exchange kinetics in platinum and ruthenium complexes,” Platinum Metals Review, vol. 52, no. 1, pp. 2–11, 2008. View at Publisher · View at Google Scholar
  14. L. Messori, A. Casini, D. Vullo, S. G. Haroutiunian, E. B. Dalian, and P. Orioli, “Effects of two representative antitumor ruthenium(III) complexes on thermal denaturation profiles of DNA,” Inorganica Chimica Acta, vol. 303, no. 2, pp. 283–286, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Gallori, C. Vettori, E. Alessio et al., “DNA as a possible target for antitumor ruthenium(III) complexes: a spectroscopic and molecular biology study of the interactions of two representative antineoplastic ruthenium(III) complexes with DNA,” Archives of Biochemistry and Biophysics, vol. 376, no. 1, pp. 156–162, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Messori, P. Orioli, D. Vullo, E. Alessio, and E. Iengo, “A spectroscopic study of the reaction of NAMI, a novel ruthenium(III) anti-neoplastic complex, with bovine serum albumin,” European Journal of Biochemistry, vol. 267, no. 4, pp. 1206–1213, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. W. H. Ang and P. J. Dyson, “Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy,” European Journal of Inorganic Chemistry, vol. 2006, no. 20, pp. 4003–4018, 2006. View at Publisher · View at Google Scholar
  18. C. X. Zhang and S. J. Lippard, “New metal complexes as potential therapeutics,” Current Opinion in Chemical Biology, vol. 7, no. 4, pp. 481–489, 2003. View at Publisher · View at Google Scholar
  19. A. Bergamo and G. Sava, “Ruthenium complexes can target determinants of tumour malignancy,” Dalton Transactions, no. 13, pp. 1267–1272, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. P. J. Dyson and G. Sava, “Metal-based antitumour drugs in the post genomic era,” Dalton Transactions, no. 16, pp. 1929–1933, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. B. K. Keppler, H. Henn, U. M. Juhl, M. R. Berger, R. Niebel, and F. E. Wagner, “New ruthenium complexes for the treatment of cancer,” in Ruthenium and Other Non-Platinum Metal Complexes in Cancer Chemotherapy, vol. 10 of Progress in Clinical Biochemistry and Medicine, pp. 41–69, Springer, Berlin, Germany, 1989. View at Publisher · View at Google Scholar
  22. C. G. Hartinger, M. A. Jakupec, S. Zorbas-Seifried et al., “KP1019, a new redox-active anticancer agent—preclinical development and results of a clinical phase I study in tumor patients,” Chemistry and Biodiversity, vol. 5, no. 10, pp. 2140–2155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Heffeter, K. Böck, B. Atil et al., “Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339,” Journal of Biological Inorganic Chemistry, vol. 15, no. 5, pp. 737–748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. C. G. Hartinger, M. A. Jakupec, S. Zorbas-Seifried et al., “KP1019, a new redox-active anticancer agent—preclinical development and results of a clinical phase I study in tumor patients,” Chemistry and Biodiversity, vol. 5, no. 10, pp. 2140–2155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Trondl, P. Heffeter, C. R. Kowol, M. A. Jakupec, W. Berger, and B. K. Keppler, “NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application,” Chemical Science, vol. 5, no. 8, pp. 2925–2932, 2014. View at Publisher · View at Google Scholar
  26. G. Sava, S. Zorzet, C. Turrin et al., “Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen,” Clinical Cancer Research, vol. 9, no. 5, pp. 1898–1905, 2003. View at Google Scholar · View at Scopus
  27. G. Sava, F. Frausin, M. Cocchietto et al., “Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A,” European Journal of Cancer, vol. 40, no. 9, pp. 1383–1396, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Pluim, R. C. A. M. van Waardenburg, J. H. Beijnen, and J. H. M. Schellens, “Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines,” Cancer Chemotherapy and Pharmacology, vol. 54, no. 1, pp. 71–78, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Kratz, B. K. Keppler, M. Hartmann, L. Messori, and M. R. Berger, “Comparison of the antiproliferative activity of two antitumour ruthenium(III) complexes with their apotransferrin and transferrin-bound forms in a human colon cancer cell line,” Metal-Based Drugs, vol. 3, no. 1, pp. 15–23, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. C. A. Smith, A. J. Sutherland-Smith, B. K. Keppler, F. Kratz, and E. N. Baker, “Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses,” Journal of Biological Inorganic Chemistry, vol. 1, pp. 424–431, 1996. View at Google Scholar
  31. A. R. Timerbaev, A. V. Rudnev, O. Semenova, C. G. Hartinger, and B. K. Keppler, “Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H- indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis,” Analytical Biochemistry, vol. 341, no. 2, pp. 326–333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Therrien, “Functionalised η6-arene ruthenium complexes,” Coordination Chemistry Reviews, vol. 253, no. 3-4, pp. 493–519, 2009. View at Publisher · View at Google Scholar
  33. R. E. Aird, J. Cummings, A. A. Ritchie et al., “In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer,” British Journal of Cancer, vol. 86, no. 10, pp. 1652–1657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. G. S. Smith and B. Therrien, “Targeted and multifunctional arene ruthenium chemotherapeutics,” Dalton Transactions, vol. 40, no. 41, pp. 10793–10800, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Clarke, “Ruthenium metallopharmaceuticals,” Coordination Chemistry Reviews, vol. 236, no. 1-2, pp. 209–233, 2003. View at Publisher · View at Google Scholar
  36. Y. N. V. Gopal, D. Jayaraju, and A. K. Kondapi, “Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action,” Biochemistry, vol. 38, no. 14, pp. 4382–4388, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Scolaro, A. Bergamo, L. Brescacin et al., “In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes,” Journal of Medicinal Chemistry, vol. 48, no. 12, pp. 4161–4171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. J. R. van Beijnum, A. Casini, A. A. Nazarov et al., “Organometallic ruthenium(II) arene compounds with antiangiogenic activity,” Journal of Medicinal Chemistry, vol. 54, no. 11, pp. 3895–3902, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Berger, M. Hanif, A. A. Nazarov et al., “In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands,” Chemistry, vol. 14, no. 29, pp. 9046–9057, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. E. E. Nifantyev, M. P. Koroteev, A. M. Koroteev et al., “Metal complexes based on monosaccharide bicyclophosphites as new available chiral coordination systems,” Journal of Organometallic Chemistry, vol. 587, no. 1, pp. 18–27, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Gras, B. Therrien, G. Süss-Fink, P. Š. Renfrew, A. K. Renfrew, and P. J. Dyson, “Water-soluble arene ruthenium complexes containing pyridinethiolato ligands: synthesis, molecular structure, redox properties and anticancer activity of the cations η6-areneRup-SC5H4NH32+,” Journal of Organometallic Chemistry, vol. 693, no. 21-22, pp. 3419–3424, 2008. View at Publisher · View at Google Scholar
  42. K. Becker, C. Herold-Mende, J. J. Park, G. Lowe, and R. Heiner Schirmer, “Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2′-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy,” Journal of Medicinal Chemistry, vol. 44, no. 17, pp. 2784–2792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. C. A. Vock, W. H. Ang, C. Scolaro et al., “Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms,” Journal of Medicinal Chemistry, vol. 50, no. 9, pp. 2166–2175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Süss-Fink, F.-A. Khan, L. Juillerat-Jeanneret, P. J. Dyson, and A. K. Renfrew, “Synthesis and anticancer activity of long-chain isonicotinic ester ligand-containing arene ruthenium complexes and nanoparticles,” Journal of Cluster Science, vol. 21, no. 3, pp. 313–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. F.-A. Khan, B. Therrien, G. Süss-Fink, O. Zava, and P. J. Dyson, “Arene ruthenium dichloro complexes containing isonicotinic ester ligands: synthesis, molecular structure and cytotoxicity,” Journal of Organometallic Chemistry, vol. 730, pp. 49–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. G. V. Tsarichenko, V. I. Bobrov, and M. V. Smarkov, “Toxicity of isonicotinic acid,” Pharmaceutical Chemistry Journal, vol. 11, no. 4, pp. 481–483, 1977. View at Publisher · View at Google Scholar · View at Scopus
  47. T. S. Morais, T. J. L. Silva, F. Marques et al., “Synthesis of organometallic ruthenium(II) complexes with strong activity against several human cancer cell lines,” Journal of Inorganic Biochemistry, vol. 114, pp. 65–74, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Moreno, M. Font-Bardia, T. Calvet et al., “DNA interaction and cytotoxicity studies of new ruthenium(II) cyclopentadienyl derivative complexes containing heteroaromatic ligands,” Journal of Inorganic Biochemistry, vol. 105, no. 2, pp. 241–249, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. M. H. Garcia, T. S. Morais, P. Florindo et al., “Inhibition of cancer cell growth by ruthenium(II) cyclopentadienyl derivative complexes with heteroaromatic ligands,” Journal of Inorganic Biochemistry, vol. 103, no. 3, pp. 354–361, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Scolaro, A. Bergamo, L. Brescacin et al., “In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes,” Journal of Medicinal Chemistry, vol. 48, no. 12, pp. 4161–4171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Serli, E. Zangrando, T. Gianferrara et al., “Is the aromatic fragment of piano-stool ruthenium compounds an essential feature for anticancer activity? The development of new RuII-[9]aneS3 analogues,” European Journal of Inorganic Chemistry, vol. 2005, no. 17, pp. 3423–3434, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Valente, M. H. Garcia, F. Marques, Y. Miao, C. Rousseau, and P. Zinck, “First polymer ‘ruthenium-cyclopentadienyl’ complex as potential anticancer agent,” Journal of Inorganic Biochemistry, vol. 127, pp. 79–81, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Maeda, G. Y. Bharate, and J. Daruwalla, “Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 71, no. 3, pp. 409–419, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Florindo, I. J. Marques, C. D. Nunes, and A. C. Fernandes, “Synthesis, characterization and cytotoxicity of cyclopentadienyl ruthenium(II) complexes containing carbohydrate-derived ligands,” Journal of Organometallic Chemistry, vol. 760, pp. 240–247, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. D. S. Williams, G. E. Atilla, H. Bregman, A. Arzoumanian, P. S. Klein, and E. Meggers, “Switching on a signaling pathway with an organoruthenium complex,” Angewandte Chemie—International Edition, vol. 44, no. 13, pp. 1984–1987, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Meggers, G. E. Atilla-Gokcumen, K. Gründler, C. Frias, and A. Prokop, “Inert ruthenium half-sandwich complexes with anticancer activity,” Dalton Transactions, no. 48, pp. 10882–10888, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Meggers, G. E. Atilla-Gokcumen, H. Bregman et al., “Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors,” Synlett, no. 8, pp. 1177–1189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. J. É. Debreczeni, A. N. Bullock, G. E. Atilla et al., “Ruthenium half-sandwich complexes bound to protein kinase Pim-1,” Angewandte Chemie International Edition, vol. 45, no. 10, pp. 1580–1585, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. D. S. Williams, G. E. Atilla, H. Bregman, A. Arzoumanian, P. S. Klein, and E. Meggers, “Switching on a signaling pathway with an organoruthenium complex,” Angewandte Chemie—International Edition, vol. 44, no. 13, pp. 1984–1987, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Bregman and E. Meggers, “Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety,” Organic Letters, vol. 8, no. 24, pp. 5465–5468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. K. S. M. Smalley, R. Contractor, N. K. Haass et al., “An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells,” Cancer Research, vol. 67, no. 1, pp. 209–217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. H.-K. Liu, S. J. Berners-Price, F. Y. Wang et al., “Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex,” Angewandte Chemie International Edition, vol. 45, no. 48, pp. 8153–8156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. R. L. Hayward, Q. C. Schornagel, R. Tente et al., “Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175,” Cancer Chemotherapy and Pharmacology, vol. 55, no. 6, pp. 577–583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. L. K. Filak, G. Mühlgassner, F. Bacher et al., “Ruthenium-and osmium-arene complexes of 2-substituted indolo[3,2- c ]quinolines: synthesis, structure, spectroscopic properties, and antiproliferative activity,” Organometallics, vol. 30, no. 2, pp. 273–283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. L. K. Filak, S. Göschl, S. Hackl, M. A. Jakupec, and V. B. Arion, “Ruthenium- and osmium-arene complexes of 8-substituted indolo[3,2-c] quinolines: synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity,” Inorganica Chimica Acta, vol. 393, pp. 252–260, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. M. F. Primik, S. Göschl, M. A. Jakupec, A. Roller, B. K. Keppler, and V. B. Arion, “Structure-activity relationships of highly cytotoxic copper(II) complexes with modified indolo[3,2-c ]quinoline ligands,” Inorganic Chemistry, vol. 49, no. 23, pp. 11084–11095, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Sharma, R. V. Singh, and N. Fahmi, “Palladium(II) and platinum(II) derivatives of benzothiazoline ligands: synthesis, characterization, antimicrobial and antispermatogenic activity,” Spectrochimica Acta—Part A: Molecular and Biomolecular Spectroscopy, vol. 78, no. 1, pp. 80–87, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. A. C. G. Hotze, S. E. Caspers, D. de Vos et al., “Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L=o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2],” Journal of Biological Inorganic Chemistry, vol. 9, no. 3, pp. 354–364, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. R. E. Morris, R. E. Aird, P. del Socorro Murdoch et al., “Inhibition of cancer cell growth by ruthenium(II) arene complexes,” Journal of Medicinal Chemistry, vol. 44, no. 22, pp. 3616–3621, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. S. W. Magennis, A. Habtemariam, O. Novakova et al., “Dual triggering of DNA binding and fluorescence via photoactivation of a dinuclear ruthenium(II) arene complex,” Inorganic Chemistry, vol. 46, no. 12, pp. 5059–5068, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Gaiddon, P. Jeannequin, P. Bischoff, M. Pfeffer, C. Sirlin, and J. P. Loeffler, “Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms,” Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 3, pp. 1403–1411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. Q. Wu, C. Fan, T. Chen et al., “Microwave-assisted synthesis of arene ruthenium(II) complexes that induce S-phase arrest in cancer cells by DNA damage-mediated p53 phosphorylation,” European Journal of Medicinal Chemistry, vol. 63, pp. 57–63, 2013. View at Publisher · View at Google Scholar
  73. W. Kandioller, C. G. Hartinger, A. A. Nazarov et al., “Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety,” Journal of Organometallic Chemistry, vol. 694, no. 6, pp. 922–929, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. W. Kandioller, C. G. Hartinger, A. A. Nazarov et al., “From pyrone to thiopyrone ligands-rendering maltol-derived ruthenium(II)-arene complexes that are anticancer active in vitro,” Organometallics, vol. 28, no. 15, pp. 4249–4251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. P. Chelopo, S. A. Pawar, M. K. Sokhela, T. Govender, H. G. Kruger, and G. E. M. Maguire, “Anticancer activity of ruthenium(II) arene complexes bearing 1,2,3,4-tetrahydroisoquinoline amino alcohol ligands,” European Journal of Medicinal Chemistry, vol. 66, pp. 407–414, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Fernández, M. Melchart, A. Habtemariam, S. Parsons, and P. J. Sadler, “Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes,” Chemistry, vol. 10, no. 20, pp. 5173–5179, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. A. S. Capilla, M. Romero, M. D. Pujol, D. H. Caignard, and P. Renard, “Synthesis of isoquinolines and tetrahydroisoquinolines as potential antitumour agents,” Tetrahedron, vol. 57, no. 39, pp. 8297–8303, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. M. A. Letavic, J. M. Keith, J. A. Jablonowski et al., “Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 4, pp. 1047–1051, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Li, H. B. Zhang, W. L. Huang, X. Zhen, and Y. M. Li, “Synthesis and biological evaluation of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer,” Chinese Chemical Letters, vol. 19, no. 2, pp. 169–171, 2008. View at Publisher · View at Google Scholar
  80. S. M. Meier, M. Hanif, Z. Adhireksan et al., “Novel metal(II) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents,” Chemical Science, vol. 4, no. 4, pp. 1837–1846, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. W. A. Kinney, N. E. Lee, R. M. Blank et al., “N-Phenyl-2-pyridinecarbothioamides as gastric mucosal protectants,” Journal of Medicinal Chemistry, vol. 33, no. 1, pp. 327–336, 1990. View at Publisher · View at Google Scholar · View at Scopus
  82. A. H. Velders, H. Kooijman, A. L. Spek, J. G. Haasnoot, D. de Vos, and J. Reedijk, “Strong differences in the in vitro cytotoxicity of three isomeric dichlorobis(2-phenylazopyridine)ruthenium(II) complexes,” Inorganic Chemistry, vol. 39, no. 14, pp. 2966–2967, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. A. H. Velders, K. van der Schilden, A. C. G. Hotze, J. Reedijk, H. Kooijman, and A. L. Spek, “Dichlorobis(2-phenylazopyridine)ruthenium(II) complexes: characterisation, spectroscopic and structural properties of four isomers,” Dalton Transactions, no. 3, pp. 448–455, 2004. View at Google Scholar · View at Scopus
  84. J. C. Chen, J. Li, L. Qian, and K. C. Zheng, “Electronic structures and SARs of the isomeric complexes α-, β-, γ- [Ru(mazpy)2Cl2] with different antitumor activities,” Journal of Molecular Structure: THEOCHEM, vol. 728, no. 1–3, pp. 93–101, 2005. View at Publisher · View at Google Scholar
  85. S. Roy, P. U. Maheswari, A. Golobic, B. Kozlevc, and J. Reedijk, “Synthesis, crystal structure and biological studies of the highly anticancer active compound trans-dichloridobis(4-methyl-2-N-(2-pyridylmethylene)-aminophenol)ruthenium(II),” Inorganica Chimica Acta, vol. 393, pp. 239–245, 2012. View at Publisher · View at Google Scholar
  86. L. M. Chen, J. Liu, J. C. Chen et al., “Experimental and theoretical studies on the DNA-binding and spectral properties of water-soluble complex [Ru(MeIm)4(dpq)]2+,” Journal of Molecular Structure, vol. 881, no. 1–3, pp. 156–166, 2008. View at Publisher · View at Google Scholar
  87. L. M. Chen, J. Liu, J. C. Chen et al., “Synthesis, characterization, DNA-binding and spectral properties of complexes [Ru(L)4(dppz)]2+ (L = Im and MeIm),” Journal of Inorganic Biochemistry, vol. 102, pp. 330–341, 2008. View at Publisher · View at Google Scholar
  88. C. W. Jiang, H. Chao, X. L. Hong, H. Li, W. J. Mei, and L. N. Ji, “Enantiopreferential DNA-binding of a novel dinuclear complex [(bpy)2Ru(bdptb)Ru(bpy)2]4+,” Inorganic Chemistry Communications, vol. 6, no. 6, pp. 773–775, 2003. View at Publisher · View at Google Scholar
  89. J. G. Liu, B. H. Ye, Q. L. Zhang et al., “Enantiomeric ruthenium(II) complexes binding to DNA: binding modes and enantioselectivity,” Journal of Biological Inorganic Chemistry, vol. 5, pp. 119–128, 2000. View at Publisher · View at Google Scholar
  90. H.-L. Huang, Z.-Z. Li, Z.-H. Liang, and Y.-J. Liu, “Cell cycle arrest, cytotoxicity, apoptosis, DNA-binding, photocleavage, and antioxidant activity of octahedral ruthenium(II) complexes,” European Journal of Inorganic Chemistry, vol. 2011, no. 36, pp. 5538–5547, 2011. View at Publisher · View at Google Scholar
  91. M. Galanski and B. K. Keppler, “Carboxylation of dihydroxoplatinum(IV) complexes via a new synthetic pathway,” Inorganic Chemistry, vol. 35, no. 6, pp. 1709–1711, 1996. View at Publisher · View at Google Scholar
  92. T. Sathiya Kamatchi, N. Chitrapriya, S. K. Kim, F. R. Fronczek, and K. Natarajan, “Influence of carboxylic acid functionalities in ruthenium (II) polypyridyl complexes on DNA binding, cytotoxicity and antioxidant activity: synthesis, structure and in vitro anticancer activity,” European Journal of Medicinal Chemistry, vol. 59, pp. 253–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Fernandez, M. Pfeffer, V. Ritleng, and C. Sirlin, “An effective route to cycloruthenated n-ligands under mild conditions,” Organometallics, vol. 18, no. 12, pp. 2390–2394, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. C. Gaiddon, P. Jeannequin, P. Bischoff, M. Pfeffer, C. Sirlin, and J. P. Loeffler, “Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms,” The Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 3, pp. 1403–1411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. V. Vidimar, X. Meng, M. Klajner et al., “Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity,” Biochemical Pharmacology, vol. 84, no. 11, pp. 1428–1436, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. L. Fetzer, B. Boff, M. Ali et al., “Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier,” Dalton Transactions, vol. 40, no. 35, pp. 8869–8878, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. X. Yang, L. Chen, Y. Liu et al., “Ruthenium methylimidazole complexes induced apoptosis in lung cancer A549 cells through intrinsic mitochondrial pathway,” Biochimie, vol. 94, no. 2, pp. 345–353, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. F. J. Huo, C. X. Yin, and P. Yang, “The crystal structure, self-assembly, DNA-binding and cleavage studies of the [2]pseudorotaxane composed of cucurbit[6]uril,” Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 4, pp. 932–936, 2007. View at Publisher · View at Google Scholar
  99. R. S. Myers, R. E. Amaro, Z. A. Luthey-Schulten, and V. J. Davisson, “Reaction coupling through interdomain contacts in imidazole glycerol phosphate synthase,” Biochemistry, vol. 44, no. 36, pp. 11974–11985, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. M. M. Kasprzak, L. Szmigiero, E. Zyner, and J. Ochocki, “Proapoptotic activity in vitro of two novel ruthenium(II) complexes with flavanone-based ligands that overcome cisplatin resistance in human bladder carcinoma cells,” Journal of Inorganic Biochemistry, vol. 105, no. 4, pp. 518–524, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. Chen, M.-Y. Qin, L. Wang, H. Chao, L.-N. Ji, and A.-L. Xu, “A ruthenium(II) β-carboline complex induced p53-mediated apoptosis in cancer cells,” Biochimie, vol. 95, no. 11, pp. 2050–2059, 2013. View at Publisher · View at Google Scholar
  102. S. L. Xiao, W. Lin, C. Wang, and M. Yang, “Synthesis and biological evaluation of DNA targeting flexible side-chain substituted β-carboline derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 4, pp. 437–441, 2001. View at Publisher · View at Google Scholar
  103. Y. Li, F. S. Liang, W. Jiang et al., “DH334, a β-carboline anti-cancer drug, inhibits the CDK activity of budding yeast,” Cancer Biology & Therapy, vol. 6, pp. 1193–1199, 2007. View at Google Scholar